Literature DB >> 34183767

Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.

Giuseppe Gritti1, Federico Raimondi2,3, Barbara Bottazzi4, Diego Ripamonti5, Ivano Riva6, Francesco Landi7,8, Leonardo Alborghetti5, Marco Frigeni7, Marianna Damiani6,9, Caterina Micò7, Stefano Fagiuoli10, Ferdinando Luca Lorini6, Lucia Gandini6,9, Luca Novelli2, Jonathan P Morgan11, Benjamin M J Owens11, Karan J K Kanhai11, Gordana Tonkovic Reljanovic12, Marco Rizzi5, Fabiano Di Marco2,13, Alberto Mantovani4,14,15, Alessandro Rambaldi7,16.   

Abstract

Entities:  

Year:  2021        PMID： 34183767     DOI： 10.1038/s41375-021-01329-8

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients.

Authors:  Scott J Morin; Chinmay Jani; Arashdeep Rupal; Harpreet Singh; Daniel Bourque; Robert C Colgrove
Journal:  Am J Ther       Date:  2021-07-05       Impact factor: 3.098

2.  Bioinformatic exploration of the immune related molecular mechanism underlying pulmonary arterial hypertension.

Authors:  Ruina Huang; Xifeng Zheng; Junxian Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.